NASA infrared data shows strength in Fengshen

Credit: Credit: NASA JPL/Heidar Thrastarson Tropical Storm Fengshen’s cold cloud top temperatures revealed that the storm was maintaining strength as a strong tropical storm. Forecasters expect Fengshen will continue strengthening and reach typhoon status. One of...

Deep neural network could improve cancer care

Improving the detection, diagnosis, and treatment of diseases like cancer will require more detailed, rapid, and agile imaging technology that can show doctors not just what a specific organ looks like, but also what's...

High expression of apoptosis protein (Api-5) in chemoresistant triple-negative breast cancers

The cover for issue 61 of Oncotarget features Figure 4, ‘The influence of stress conditions on API-5 expression and inhibition,’ by Bousquet, et al. Credit: Correspondence to – Melanie Di Benedetto – melanie.dibenedetto@univ-paris13.fr and Guilhem...

Mass Layoffs as Dutch Biotech Cancels Phase III Cell Therapy Trial

The Dutch company Kiadis Pharma has discontinued the development of a cell therapy in blood cancer, laid off half of its workforce, and switched focus to other, less advanced cell therapy programs. The abandoned phase...

Johns Hopkins launches new center for ‘immunoengineering’ research

If the saying that two heads are better than one is true, then joining two fields of science may be better than one to spur more advances in medicine. With a $6.7 million, five-year...

Merck Acquires TRPML1 Agonist Developer Calporta for Up to $576M

Sanford J. Madigan, PhD, CEO of Calporta and senior vice president, business development of COI Pharmaceuticals. Merck & Co. has acquired Calporta, a developer of treatments for neurodegenerative and lysosomal storage disorders, for up to...

Nail Your Biotech Career with These Exciting Jobs

Hello biotechies,Job hunt frustration? Don’t worry, we’re here to help. Check out the exclusive offer from DNA Script or become a scientist at Oxford Biomedica. Just starting out? Check out the internship at Miltenyi...

Vir Biotechnology’s Quiet Period Set To End on November 20th (NYSE:VIR) – Polson News

Vir Biotechnology’s (NYSE:VIR) quiet period will end on Wednesday, November 20th. Vir Biotechnology had issued 7,142,858 shares in its IPO on October 11th. The total size of the offering was $142,857,160 based on an...

Cardiac-specific biomarkers may help predict CVD risk factors early

A new review article provides valuable insights into how traditional and emerging cardiac-specific biomarkers and their associated cardiovascular disease (CVD) risk factors may help point to effective preventive interventions in high-risk obese populations starting...

AI-driven single blood cell classification

New method to support physicians in leukemia diagnostics Credit: ©Helmholtz Zentrum München / Carsten Marr Every day, millions of single blood cells are evaluated for disease diagnostics in...

Stay connected

43,732FollowersFollow
14,000SubscribersSubscribe

Recent posts

Random article